Financial Performance - Lantheus reported revenues of $384 million for Q3 2025, a 1.4% increase year-over-year[13, 35] - Adjusted EPS for Q3 2025 was $1.27, a 25.3% decrease year-over-year[13, 35] - Radiopharmaceutical Oncology sales were $240.6 million, a 7.4% decrease year-over-year, while U S volumes grew by 3 3%[35, 19] - Precision Diagnostics sales were $129.7 million, a 25 0% increase year-over-year, driven by DEFINITY sales growth of 6 3% and the addition of Neuraceq[35, 21] - Strategic Partnerships sales were $13.7 million, a 10.1% decrease year-over-year[35] Strategic Initiatives and Pipeline - Lantheus completed the acquisition of Life Molecular Imaging and repurchased $100 million of stock during the quarter[39] - The company anticipates four key product approvals by year-end 2026, including a new PSMA PET imaging agent, MK-6240, LNTH-2501, and PNT2003[15, 46] - Lantheus is expanding geographic coverage for Alzheimer's disease imaging, aiming for broad access across leading centers and community practices[25] - The company is advancing MK-6240, a F18 PET imaging agent for detecting tau in adults being evaluated for Alzheimer's disease, with a PDUFA date of August 13, 2026[29, 31] Financial Guidance - Lantheus updated its FY 2025 revenue guidance to $1.49 billion-$1.51 billion[42] - The company updated its FY 2025 adjusted fully diluted EPS guidance to $5.50-$5.65[42]

Product Development and Pipeline - The company reported a significant focus on expanding its product pipeline, particularly in radiopharmaceutical oncology and precision diagnostics, with a commitment to improving patient outcomes [175]. - The FDA has set a PDUFA target action date of March 29, 2026, for LNTH-2501, a diagnostic kit for Gallium-68 edotreotide Injection, aimed at neuroendocrine tumors [181]. - The company announced the acceptance of its New Drug Application for MK-6240, with a PDUFA target action date of August 13, 2026, following successful pivotal studies [182]. - The company aims to optimize the manufacturing process of its F-18 PSMA PET imaging agent, potentially increasing batch size by approximately 50% [184]. - The company plans to submit an NDA for NAV-4694 in 2026, following an upfront payment of $32.9 million for the investigational asset [223]. Acquisitions and Partnerships - An exclusive licensing agreement was established with GE HealthCare for the development and commercialization of piflufolastat F-18 in Japan, with upfront fees and royalties based on sales [183]. - The acquisition of Life Molecular Imaging Ltd. was completed for an upfront payment of $355.2 million, with potential additional payments of up to $400 million based on milestones [186][187]. - The company acquired Evergreen Theragnostics, Inc. for an upfront payment of $276.4 million, with potential additional payments of up to $727.5 million based on milestone achievements [191][192]. - The company acquired NAV-4694, an investigational PET imaging agent for Alzheimer's disease, for an upfront payment of $32.9 million, with additional payments contingent on regulatory milestones [194][195]. - The company entered into an agreement with Radiopharm for preclinical assets, paying an upfront amount of $2.0 million, and assumed related milestone and royalty obligations [197][198]. - The company entered into a definitive agreement to sell its SPECT business to SHINE, allowing a focus on growing its PET radiodiagnostics portfolio [193]. Financial Performance - The company reported revenues of $384.0 million for the three months ended September 30, 2025, representing a 1.4% increase from $378.7 million in the same period of 2024 [230]. - Cost of goods sold increased by 18.3% to $161.6 million for the three months ended September 30, 2025, compared to $136.6 million in the prior year [230]. - Gross profit decreased by 8.2% to $222.4 million for the three months ended September 30, 2025, down from $242.1 million in 2024 [230]. - Operating expenses rose by 64.9% to $178.8 million for the three months ended September 30, 2025, compared to $108.4 million in the same period of 2024 [230]. - Net income for the three months ended September 30, 2025, was $27.8 million, a decrease of 78.8% from $131.1 million in 2024 [230]. - Revenues for the three months ended September 30, 2025, increased by $5.3 million (1.4%) to $384.0 million compared to the same period in 2024, primarily driven by sales of Neuraceq and increased DEFINITY sales volume [232]. - For the nine months ended September 30, 2025, total revenues decreased by $8.0 million (0.7%) to $1,134.8 million, mainly due to a decrease in the net sales price of PYLARIFY and a decrease in TechneLite sales volume [233]. Expenses and Costs - The company reported a significant increase in general and administrative expenses, which rose by 102.1% to $81.9 million for the three months ended September 30, 2025 [230]. - Sales and marketing expenses increased by $5.1 million for the three months ended September 30, 2025, due to increased sales costs related to Neuraceq and contract manufacturing services [239]. - R&D expenses increased by $23.9 million for the three months ended September 30, 2025, primarily due to the impact of acquisitions and investments in late-stage assets [244]. - General and administrative expenses rose by $41.4 million and $69.4 million for the three and nine months ended September 30, 2025, respectively, driven by the impact of acquisitions and increased professional fees [242]. Cash Flow and Financing - Net cash provided by operating activities was $300.0 million for the nine months ended September 30, 2025, a decrease from $387.0 million in the same period of 2024 [251]. - Net cash used in investing activities was $615.7 million for the nine months ended September 30, 2025, significantly higher than $219.4 million in the same period of 2024, primarily due to acquisitions [254]. - Net cash used in financing activities for the nine months ended September 30, 2025, was approximately $200.0 million, primarily due to stock repurchases [256]. - The company issued $575.0 million in Convertible Senior Notes due 2027, with net proceeds of approximately $557.8 million [262]. - The company amended its revolving credit facility, increasing the commitment from $350.0 million to $750.0 million and extending the maturity date to December 19, 2029 [206][207]. Market Position and Future Outlook - PYLARIFY, an F-18 PET imaging agent, was launched in June 2021 and is expected to maintain its position as the most utilized PSMA PET imaging agent despite increasing competition [208][209]. - DEFINITY is expected to maintain at least an 80% market share in the U.S. for ultrasound enhancing agents in echocardiography procedures [212][213]. - Neuraceq revenue growth will depend on increased adoption of beta-amyloid PET and anti-amyloid therapeutics, along with expanded geographical access and enhanced manufacturing capacity [214]. - Future capital requirements will depend on product sales, pricing environment, and ongoing commercialization costs [266]. - The company may need to finance cash needs through public or private equity offerings or debt financings if capital resources become insufficient [268]. Leadership and Strategic Focus - The leadership transition plan includes the retirement of the CEO by December 31, 2025, with an interim CEO appointed to lead the company during the search for a new CEO [179][180]. - The strategic focus includes expanding into new markets and enhancing development capabilities through acquisitions and partnerships [178]. - The company is focused on expanding its Strategic Partnerships and Other Revenue category, particularly in radiopharmaceuticals for oncology and neurology [215].

Exhibit 99.1 Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update BEDFORD, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2025. "Lantheus' third quarter results underscore the strength of our s ...

Core Insights - Lantheus Holdings, Inc. reported third quarter 2025 financial results, highlighting a slight increase in worldwide revenue but significant declines in net income and earnings per share [3][7][8] - The company is focusing on the commercial execution of its prostate cancer franchise, particularly PYLARIFY, while also advancing its strategic diversification plan [2][5] Financial Performance - Worldwide revenue for Q3 2025 was $384.0 million, a 1.4% increase from $378.7 million in Q3 2024 [3][21] - GAAP net income decreased by 78.8% to $27.8 million compared to $131.1 million in the prior year [3][8] - GAAP fully diluted earnings per share fell by 77.1% to $0.41 from $1.79 in Q3 2024 [3][8] - Adjusted net income (non-GAAP) was $85.7 million, down 30.9% from $124.1 million in the previous year [3][8] - Adjusted fully diluted earnings per share (non-GAAP) decreased by 25.3% to $1.27 from $1.70 [3][8] Business Developments - The company announced the retirement of CEO Brian Markison effective December 31, 2025, and is conducting a search for a new CEO [5][7] - Lantheus closed the acquisition of Life Molecular Imaging in July 2025, enhancing its commercial portfolio [7][16] - The company repurchased $100 million of its common stock in Q3 2025 as part of its stock repurchase plan [7][8] Product Sales - Sales of PYLARIFY were $240.6 million, a decrease of 7.4% year-over-year [8][21] - Sales of DEFINITY increased by 6.3% to $81.8 million [8][21] - Operating income decreased by 67.4% to $43.6 million, while adjusted operating income (non-GAAP) fell by 27.6% to $119.6 million [8][21] Cash Flow and Balance Sheet - Free cash flow for Q3 2025 was $94.7 million, down from $159.3 million in Q3 2024 [8][26] - As of September 30, 2025, cash and cash equivalents were $382.0 million, significantly reduced from $912.8 million at the end of 2024 [8][27] Guidance - The updated corporate guidance for full year 2025 revenue is projected to be between $1.49 billion and $1.51 billion [10] - Adjusted fully diluted earnings per share guidance for FY 2025 is set at $5.50 to $5.65 [10]

Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Chief Executive Officer Brian Markis ...

LANTHEUS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTHNovember 05, 2025 9:20 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and A ...

Accessibility StatementSkip Navigation You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at [email protected]. Lead plaintiff motions for the Lantheys class action lawsuit must be filed with the court no later than Monday, November 10, 2025. CASE ALLEGATIONS: Lantheus presents itself as a sophisticated medical technology company driving innovation in radiopharmaceuticals. Lantheus's flagship product is Pylarify, a prostate-specific ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3][5]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4]. Group 3: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding its product Pylarify, failing to disclose critical information about its competitive position and pricing strategy [5]. - It is claimed that Lantheus's price increase in early 2025, despite previous price erosion, created risks for Pylarify's pricing and revenue potential, leading to investor damages when the true situation was revealed [5].

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the sales growth of its product Pylarify [2]. - It is alleged that Lantheus downplayed risks associated with competition, pricing dynamics, seasonality, and macroeconomic fluctuations, leading to an inaccurate portrayal of its market understanding [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].